NLS Pharmaceutics Exchanges Warrants with Alpha Capital

Ticker: NCEL · Form: 6-K · Filed: Aug 6, 2025 · CIK: 1783036

Nls Pharmaceutics LTD. 6-K Filing Summary
FieldDetail
CompanyNls Pharmaceutics LTD. (NCEL)
Form Type6-K
Filed DateAug 6, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: warrant-exchange, capital-markets, debt-restructuring

TL;DR

NLS Pharma swapped old warrants for new ones with Alpha Capital.

AI Summary

On August 5, 2025, NLS Pharmaceutics Ltd. entered into a warrant exchange agreement with Alpha Capital Anstalt. This agreement involves the exchange of a common share purchase warrant dated October 10, 2024, which was originally for 207,913 common shares.

Why It Matters

This warrant exchange could impact the number of outstanding shares and potentially dilute existing shareholders if the warrants are exercised.

Risk Assessment

Risk Level: medium — Warrant exchanges can lead to changes in share structure and potential dilution, affecting stock value.

Key Numbers

Key Players & Entities

FAQ

What are the specific terms of the new warrant being exchanged?

The filing does not specify the terms of the new warrant, only that an exchange occurred for a warrant originally dated October 10, 2024, for 207,913 common shares.

What is the reason for this warrant exchange?

The filing does not provide a specific reason for the warrant exchange, only that an agreement was entered into.

Does this exchange involve any cash payment from NLS Pharmaceutics Ltd.?

The filing describes an 'exchange' and does not mention any cash payment from NLS Pharmaceutics Ltd. to Alpha Capital Anstalt.

When was the original warrant issued?

The original warrant was dated October 10, 2024.

Who is Alpha Capital Anstalt?

Alpha Capital Anstalt is identified as the 'Holder' of the common share purchase warrant that was exchanged.

Filing Details

This Form 6-K (Form 6-K) was filed with the SEC on August 6, 2025 regarding NLS Pharmaceutics Ltd. (NCEL).

View full filing on EDGAR

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing